Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are between 18 and 69 years old (inclusive) at the time of signing the consent form
- People whose Body Mass Index (BMI — a measure of weight relative to height) falls between 27.0 and 40.0 at the screening stage
- People whose liver contains 8% or more fat, as measured by a specific type of MRI scan, within 17 days before the first dose
- People who have no history (past or present) of a formal diagnosis of a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) — a more severe form of fatty liver disease (confirm with trial site)
Who may not be able to join:
- People whose overall health condition, in the treating doctor's judgement, could put their safety at risk or make it hard to follow the trial requirements
- People who have previously used, or are currently using, any approved or trial-based treatments specifically for MASH or for liver scarring (fibrosis)
- People who have used any of the following within the 6 months before screening: high-dose vitamin E (more than 800 IU per day), certain blood sugar or weight-related medications including liraglutide, dulaglutide, semaglutide, tirzepatide, or pioglitazone
- People whose liver enzyme levels (AST or ALT — markers of liver stress measured in a blood test) are 1.5 times or more above the normal upper limit at screening
- People whose total bilirubin level (a substance measured in blood that reflects liver function) is more than 1.5 times the normal upper limit, unless a related measure called direct bilirubin is within the normal range (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency' (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Treatment-emergent adverse event (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.